

829 Right lateral prefrontal cortex—specificity for inhibition or strategy use? M. Hornberger and M. Bertoux

Original Articles

833 Where is hippocampal activity in motor neuron degeneration. T. C. Watson, et al.


916 Eltoprazine counteracts L-DOPA-induced dyskinesias in Parkinson’s disease: a dose–finding study. F. Barkhof and J. J. G. Geurts

852 Defects of mutant DNMT1 are linked to a spectrum of neurological disorders. J. Baets, X. Duan, Y. Wu, et al.

839 Seizure suppression through manipulating splicing of a voltage-gated sodium channel. W.-H. Lin, M. He and R. A. Baines


946 Reduced cortical innervation of the subthalamic nucleus in MPTP-reated parkinsonian monkeys. A. Mathis, T. Ma, J.-A. Witt, et al.

922 Neuronal death induced by misfolded prion protein is due to NAD+ depletion and can be relieved in vitro and in vivo by NAD+ replenishment. M. Zhou, G. Ottenberg, G. F. Sferrazza, et al.


8111 Forgotten bodies too? D. Falk

1113 The body electric: a long view of electrical therapy for functional neurological disorders. L. McWhirter, A. Carson and J. Stone


1097 Therapy-induced brain reorganisation patterns in aphasia. S. Abel, C. Weiller, W. Haber, et al.


921 The role of the hippocampal CA1 field for declarative memory formation? J.-A. Witt, C. Helmstaedter and C. E. Elger

1023 Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. W. Hukries, E. C. Launer, A. P. Schulz, et al.

1097 Therapeutic-induced brain reorganisation patterns in aphasia. S. Abel, C. Weiller, W. Haber, et al.